The Board of Directors of St.Galler Kantonalbank proposes Cornelia Stengel, attorney-at-law, as a member of the Board of Directors at the Annual General Meeting on 1 May 2024. Prof. Dr. iur. Cornelia Stengel has worked as
ANYbotics, a renowned maker of four-legged robots, announced the closing of its CHF 45 million series B financing round. The financing round was led by Walden Catalyst Ventures and included the participation of the co-investors NGP
Homburger advised the initial purchasers and arrangers in connection with CABB group’s EUR 250 million senior secured floating rate notes and EUR 420 million 8.75% senior secured fixed rate notes due 2028 and a new EUR 110 million revolving
Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a pioneering and unique solution for ecological and sustainable investments in gold. The company has issued and listed a new exchange traded product (ETP) on
Alessandro Celli, partner at Baker McKenzie Switzerland, speaks. “We have created a data-driven team.” by giuseppe salemme Alessandro Celli is a partner at Baker Mckenzie Switzerland and head of the Swiss Tmt practice group. He
NKF advised Ecorobotix as Swiss counsel on its CHF 46 million Series B Prime financing round led by AQTON Private Equity and Cibus Capital. Additional investments came from Swisscanto Invest/Swisscanto Growth Fund I, Yara Growth
With the legal representation by Lenz & Staehelin‘s Jürg Simon (pictured) and Milano based legal professional, Cesare Galli, Emmentaler Switzerland, the producer organization of Emmentaler AOP, has recently achieved a significant victory in
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
Siegfried and DiNAQOR entered into an agreement relating to the acquisition by Siegfried of a 95% stake in DiNAQOR DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and
Daniel Haymann joins MME from MLL and becomes Counsel. He specialises in corporate and commercial law. Based on his extensive business experience, he has a good feel for new markets and understands the requirements of
